TY - JOUR
T1 - Validation of HB-EGF and amphiregulin as targets for human cancer therapy
AU - Yotsumoto, Fusanori
AU - Yagi, Hiroshi
AU - Suzuki, Satoshi O.
AU - Oki, Eiji
AU - Tsujioka, Hiroshi
AU - Hachisuga, Touru
AU - Sonoda, Kenzo
AU - Kawarabayashi, Tatsuhiko
AU - Mekada, Eisuke
AU - Miyamoto, Shingo
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas (No. 17014057) and Research Promotion for Innovative Therapies against Cancers from the Ministry of Education, Culture, Sports, Science and Technology to E.M.
PY - 2008/1/18
Y1 - 2008/1/18
N2 - Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.
AB - Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=36549072385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36549072385&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2007.11.015
DO - 10.1016/j.bbrc.2007.11.015
M3 - Article
C2 - 18023415
AN - SCOPUS:36549072385
SN - 0006-291X
VL - 365
SP - 555
EP - 561
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 3
ER -
